Parse Biosciences Launches Certified Service Provider Program
2024年7月11日 - 9:15PM
ビジネスワイヤ(英語)
Eurofins Clinical Enterprise, LLC and
SeqMatic first providers to join program, expanding access to
Parse’s growing single cell portfolio
Parse Biosciences, a leading provider of accessible and scalable
single cell sequencing solutions, today announced the launch of its
Certified Service Provider (CSP) Program. For researchers who are
seeking paths to outsource their single cell projects, Parse’s CSP
Program provides options to partner with trusted service providers
capable of running smaller pilot projects up to performing routine
high throughput projects.
Fremont, California-based SeqMatic and Framingham,
Massachusetts-based Eurofins Clinical Enterprise, LLC are the first
CSPs to partner with Parse to offer its expanding portfolio of
single cell products, including its Evercode™ Whole Transcriptome,
Evercode™ TCR, CRISPR Detect, Gene Capture, and its recently
released Evercode™ BCR, which captures full length BCR sequences
and gene expression together at unprecedented scale.
“The advances we’re seeing as a result of single cell sequencing
continue to transform scientific research,” noted Parse co-founder
and CEO Alex Rosenberg. “The CSP Program is an important step in
broadening access to scalable single cell sequencing, and we’re
proud to have SeqMatic and Eurofins Clinical Enterprise join us as
our first partners in this initiative.”
Comprehensive CSPs providing a full range of high quality
end-to-end multi omics workflow solutions including DNA and RNA
sequencing, SeqMatic and Eurofins Clinical Enterprise can manage
samples from any US or international location, including multi-site
collaborations and unique requirements. Their professional service
provides assurance of expert handling, tracking and coordination of
samples.
“SeqMatic is dedicated to providing the highest level of service
and cutting edge technologies to our more than 700 customers in the
US and around the world,” said SeqMatic CEO Len Goren. “We are
excited to make Parse’s industry-leading single cell sequencing
kits available to all of them.”
Partner companies like SeqMatic and Eurofins Clinical Enterprise
that offer Parse’s kits as a service must meet Parse’s stringent
criteria and provide the highest quality results to their clients.
For more information about Parse’s CSP program, visit
https://www.parsebiosciences.com/service-providers/. To learn more
about SeqMatic’s Parse offerings, visit
https://www.seqmatic.com/services/parse-biosciences-single-cell-rna-sequencing-service/,
and to learn more about Eurofins Clinical Enterprise’s Parse
offerings, visit https://clinicalenterprise.com/.
About Parse Biosciences
Parse Biosciences is a global life sciences company whose
mission is to accelerate progress in human health and scientific
research. Empowering researchers to perform single cell sequencing
with unprecedented scale and ease, its pioneering approach is
enabling groundbreaking discoveries in cancer treatment, tissue
repair, stem cell therapy, kidney and liver disease, brain
development, and the immune system.
Founded based on a transformative technology invented at the
University of Washington, Parse has raised over $100 million and is
used in nearly 2,000 labs across the world. Its growing portfolio
of products includes Evercode Whole Transcriptome, Evercode TCR,
Evercode BCR, CRISPR Detect, Gene Capture, and a software tool for
data analysis.
Headquartered in Seattle, Washington’s vibrant South Lake Union
district, Parse Biosciences recently opened a 34,000 square foot
headquarters and state-of-the-art laboratory.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240711445815/en/
Jay Roberts, SRPR jay@shevrushpr.com | 917.696.2142